Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Status: | Completed |
---|---|
Conditions: | Allergy |
Therapuetic Areas: | Otolaryngology |
Healthy: | No |
Age Range: | Any |
Updated: | 2/4/2013 |
Start Date: | January 2013 |
End Date: | May 2013 |
Contact: | Jon Williams, PhD |
Email: | jon.williams@bausch.com |
Phone: | (949) 788-5334 |
A Dose-Ranging Study to Evaluate the Safety and Efficacy of Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects With a Demonstrated History of Mountain Cedar Pollen Allergic Sensitivity
This study will examine dose ranging characteristics of bepotastine besilate nasal spray
compared to placebo nasal spray in 600 male or female subjects 12 years of age and older
with active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic
sensitivity to Mountain Cedar pollen for at least 2 years prior to the study.
Inclusion Criteria:
- The subject is a male or female 12 years of age or older.
- Have a documented history of SAR resulting from exposure to Mountain Cedar pollen for
a minimum of 2 years immediately preceding Screening Visit 1.
- Have demonstrated sensitivity to Mountain Cedar pollen through a standard skin prick
test.
- Have a minimum rTNSS of at least 6 units for the AM assessment on the day of Visit 2
and Visit 3.
- Have a minimum average rTNSS score of at least 6 units for 3 of the worst 4 days
prior to Visit 3 plus the AM assessment on the day of Visit 3.
- Have a minimum stuffy nose score of at least 2 units on the day of Visit 3.
- Have a minimum average stuffy nose score of at least 2 units for 3 of the worst 4
days prior to Visit 3 plus the AM assessment on the day of Visit 3.
- Have at least one score ≥ 2 units at Visit 3 of any of the RQLQ(S) questions #4-#6
regarding sleep.
Exclusion Criteria:
- Have a nasal condition which, in the opinion of the Investigator, interferes with
successful nasal drug administration or absorption (in either nostril) within the
last 60 days prior to Screening Visit 2.
- Have asthma requiring medication other than intermittent use of an inhaled
short-acting β-agonist.
- Is participating or have participated in any investigational drug or device study
within 30 days preceding Visit 2.
- Have had nasal or sinus surgery within 12 weeks of Visit 2.
- Have a known sensitivity to bepotastine besilate or any excipient component of the
IP.
- For female subjects 12 years of age or older (other than those who have been
menopausal for at least 24 months or those who are surgically sterile), are pregnant,
planning to become pregnant, or nursing/lactating, or refuses to abide by the
contraception stipulations in the inclusion criteria.
We found this trial at
1
site
Click here to add this to my saved trials